New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow